ESMO 2017 Highlights in Lung Cancer: A Paradigm Shift

Speaker: Julien Mazières

Julien Mazières states that this meeting has been very important for the lung cancer community with practice changing results in the treatment of many NSCLC patients.

Julien Mazières states that this meeting has been very important for the lung cancer community with practice changing results in the treatment of many NSCLC patients.

The PACIFIC study in locally advanced NSCLC shows the activity of an anti-PD-L1 agent in a setting where we haven't seen any progress in a decade. Luis Paz-Ares reports an 11 months difference in median PFS, with consistent results from prior studies and manageable toxicities. It opens a new standard of care for this setting.

The results from the FLAURA study are very impressive with a primary end point of 54% reduction in the risk of death or progression, reports Suresh Ramalingam. It should convince every physician to use osimertinib as first-line treatment for EGFR mutated patients. Additional data on survival and resistance mechanisms would be important to anticipate further lines of treatment.

The BRAF V600E mutation is rare but patients with metastatic NSCLC should be tested for this. The C branch of the study presented by David Planchard showed excellent results with the combination of dabrafenib plus trametinib which should become the standard of care for these patients.

The IFCT-0302 trial addresses the very important and practical routine question of early stage lung cancer patients’ follow-up after thoracic surgery. Virginie Westeel reports that additional CT scans did not show any benefit in the first 24 months but helped detect secondary lung cancer after 2 years.

 

Abstracts

  • LBA1_PR PACIFIC: A double-blind, placebo-controlled Phase III study of durvalumab after chemoradiation therapy (CRT) in patients with Stage III, locally advanced, unresectable NSCLC
  • LBA2_PR - Osimertinib vs SoC EGFR-TKI as first-line treatment in patients with EGFRm advanced NSCLC (FLAURA)
  • LBA51 - Phase 2 Trial (BRF113928) of Dabrafenib (D) Plus Trametinib (T) in Patients (pts) With Previously Untreated BRAF V600E–Mutant Metastatic Non-Small Cell Lung Cancer (NSCLC)
  • 1273O_PR - Results of the phase III IFCT-0302 trial assessing minimal versus CT-scan-based follow-up for completely resected non-small cell lung cancer (NSCLC)

More resources from ESMO 2017 Congress